50. Dermatomyositis Clinical trials / Disease details
Clinical trials : 182 / Drugs : 229 - (DrugBank : 88) / Drug target genes : 48 - Drug target pathways : 147
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00005571 (ClinicalTrials.gov) | April 2000 | 25/4/2000 | Safety and Effectiveness of h5G1.1-mAb for Dermatomyositis | A Randomized, Third-Party-Blind, Placebo-Controlled Pilot Study of the Effect of h5G1.1-mAb on Dermatomyositis Patients | Dermatomyositis | Drug: h5G1.1-mAb | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | NULL | Completed | N/A | N/A | Both | 17 | Phase 2 | United States |